Johnson & Johnson stated Thursday it had filed for approval from European regulators for its two-dose experimental vaccine to protect against Ebola, less than a month after the company recommended approval of Merck & Co’s vaccine.
J&J stated it submitted two marketing authorization applications to the European Medicines Agency (EMA) for its vaccine routine targeting the Zaire strain of the Ebola virus, which mostly causes outbreaks of the deadly illness.
The corporate’s vaccine requires two injections administered about eight weeks apart, the primary developed utilizing J&J’s technology and the second from Denmark-based biotech Bavarian Nordic.
J&J’s applications are supported by data from more than10 research, which have tested the regimen in adults and kids, the corporate stated.
The drug manufacturer added it was discussing with the Food and Drug Administration (FDA) the dataset that would be needed for U.S. permits.
Since it first began in August last year, the Ebola epidemic has killed over 2,000 people, second only to the 2013-16 epidemic in West Africa that killed more than 11,300.
The EMA’s recommendation for approval last month of Merck’s Ebola vaccine, taken as a single shot, was welcomed by the World Health Organization (WHO) as a “win for public health” that would save many people.
This month, health authorities in the Democratic Republic of Congo are introducing J&J’s vaccine to counter the current epidemic within the nation’s eastern regions, where Merck’s vaccine is already in use.
J&J’s subsidiary Janssen is also working in partnership with WHO to allow registration of the Ebola vaccine regimen in African nations, the company stated.